Pfizer’s one-time haemophilia B therapy Beqvez granted FDA approval
More than 38,000 people worldwide are currently affected by the rare genetic bleeding disorder
Read More
Apr 29, 2024 | News, Regulatory
More than 38,000 people worldwide are currently affected by the rare genetic bleeding disorder
Read MoreApr 29, 2024 | News, Regulatory
The fully-human EGFR-MET bispecific antibody has been recommended as a first-line treatment option
Read MoreApr 26, 2024 | News, Regulatory
Under the brand name Tevimbra, the company will combine the NSCLC indications with the second-line ESCC indication in late 2024
Read MoreApr 26, 2024 | News, Regulatory
The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra
Read MoreApr 25, 2024 | News, Regulatory
The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse
Read MoreApr 25, 2024 | News, Regulatory
Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years
Read MoreApr 25, 2024 | News, Regulatory
The incidence of neuroendocrine tumours has increased over the past several decades
Read MoreApr 25, 2024 | News, Regulatory
The type 2 RAF inhibitor is the first and only one approved in the US to treat this patient population
Read MoreApr 24, 2024 | News, Regulatory
Gliomas are the most common type of brain cancer in paediatric patients
Read MoreApr 24, 2024 | News, Regulatory
The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors
Read MoreApr 24, 2024 | News, Regulatory
NMIBC accounts for up to 80% of bladder cancer cases, the tenth most commonly diagnosed cancer globally
Read MoreApr 23, 2024 | News, Regulatory
Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health
Read MoreAccount Specialist - Respiratory - Kent & Medway
Marketing Manager - Aesthetics - Hertfordshire
Account Manager - Nutrition - Herts/Northants/Bucks/W Essex
National Field Trainer - Oncology - UK Wide